Recce Pharmaceuticals Partners with USAMRIID for Biodefense Pathogen Testing

Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an update.

Recce Pharmaceuticals has entered into a Cooperative Research and Development Agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), supported by the Defense Threat Reduction Agency. This agreement will involve testing Recce’s synthetic anti-infective, RECCE 327, against biodefense pathogens in USAMRIID’s high biocontainment facilities. This partnership complements a recent US$2 million grant from the U.S. Department of Defense for a burn wound program, enhancing Recce’s collaboration with U.S. Government initiatives and potentially advancing the development of R327 as a treatment for severe infections.

More about Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd. is a company focused on developing a new class of synthetic anti-infectives. Their primary product, RECCE 327, is a broad-spectrum anti-infective effective against both Gram-positive and Gram-negative bacteria, including drug-resistant superbugs. The company is engaged in partnerships with U.S. Government agencies to accelerate the development of therapeutic compounds with broad-spectrum antibacterial activity.

YTD Price Performance: -39.58%

Average Trading Volume: 210,742

Technical Sentiment Signal: Buy

Current Market Cap: A$78.45M

For an in-depth examination of RCE stock, go to TipRanks’ Stock Analysis page.